[
  {
    "ts": "2026-02-04T02:49:00+00:00",
    "headline": "Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off",
    "summary": "The company expects to launch more than 20 pivotal late-stage trials this year.",
    "url": "https://www.fool.com/investing/2026/02/03/why-2026-could-be-the-year-pfizers-stock-finally-t/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "7554d91e-d731-3faf-bcf8-f55b3dd14c5f",
      "content": {
        "id": "7554d91e-d731-3faf-bcf8-f55b3dd14c5f",
        "contentType": "STORY",
        "title": "Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off",
        "description": "",
        "summary": "The company expects to launch more than 20 pivotal late-stage trials this year.",
        "pubDate": "2026-02-04T02:49:00Z",
        "displayTime": "2026-02-04T02:49:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/9e4382f80790eefdafaf9ad8b5520c94",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Investor at home looking at multiple charts.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AImvCKGUIyc2oDC.pzXokw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/9e4382f80790eefdafaf9ad8b5520c94.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TdGMztVHqpgyf3kAjQrwtw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/9e4382f80790eefdafaf9ad8b5520c94.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/03/why-2026-could-be-the-year-pfizers-stock-finally-t/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-2026-could-pfizers-stock-024900212.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T05:13:36+00:00",
    "headline": "Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth Story",
    "summary": "Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from Metsera. The company outlined plans to launch an expansive late stage development program, including more than 20 pivotal studies and multiple Phase 3 trials. The GLP-1 program targets the growing obesity treatment market at a time when Pfizer is addressing revenue pressure from lower COVID-19 product demand and upcoming patent expirations. For you as an investor, this...",
    "url": "https://finance.yahoo.com/news/pfizer-bets-monthly-glp-1-051336350.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "7531535b-ae14-3dc0-a2e9-cc6ae1a0f948",
      "content": {
        "id": "7531535b-ae14-3dc0-a2e9-cc6ae1a0f948",
        "contentType": "STORY",
        "title": "Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth Story",
        "description": "",
        "summary": "Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from Metsera. The company outlined plans to launch an expansive late stage development program, including more than 20 pivotal studies and multiple Phase 3 trials. The GLP-1 program targets the growing obesity treatment market at a time when Pfizer is addressing revenue pressure from lower COVID-19 product demand and upcoming patent expirations. For you as an investor, this...",
        "pubDate": "2026-02-04T05:13:36Z",
        "displayTime": "2026-02-04T05:13:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-bets-monthly-glp-1-051336350.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-bets-monthly-glp-1-051336350.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T06:08:05+00:00",
    "headline": "Pfizer Q4 Earnings Call Highlights",
    "summary": "Pfizer (NYSE:PFE) executives used the company’s fourth-quarter 2025 earnings call to highlight outperformance versus internal commitments, continued progress in recently launched and acquired brands, and a major research update tied to its obesity pipeline. Management also reaffirmed 2026 guidance w",
    "url": "https://www.marketbeat.com/instant-alerts/pfizer-q4-earnings-call-highlights-2026-02-04/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "41cabc78-4b3d-3dff-bace-5f87a5a1c997",
      "content": {
        "id": "41cabc78-4b3d-3dff-bace-5f87a5a1c997",
        "contentType": "STORY",
        "title": "Pfizer Q4 Earnings Call Highlights",
        "description": "",
        "summary": "Pfizer (NYSE:PFE) executives used the company’s fourth-quarter 2025 earnings call to highlight outperformance versus internal commitments, continued progress in recently launched and acquired brands, and a major research update tied to its obesity pipeline. Management also reaffirmed 2026 guidance w",
        "pubDate": "2026-02-04T06:08:05Z",
        "displayTime": "2026-02-04T06:08:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/d1514fc857a4103ec58c4c38395ac3df",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Pfizer logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gN0qDzlKmNtqujKAy1Iq7A--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/d1514fc857a4103ec58c4c38395ac3df.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5fyF8KYGugAxs5A_Chyvpw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/d1514fc857a4103ec58c4c38395ac3df.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/pfizer-q4-earnings-call-highlights-2026-02-04/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-q4-earnings-call-highlights-060805182.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T04:09:48+00:00",
    "headline": "Asian shares gained and gold and silver climb higher after a retreat on Wall St",
    "summary": "Asia shares traded mostly higher on Wednesday despite a retreat on Wall Street on selling of technology stocks, while gold and silver continued to regain ground after a recent sell-off. U.S. futures edged higher and oil prices advanced. The future for the S&P 500 edged up 0.2%, while that for the Dow Jones Industrial Average rose 0.3%.",
    "url": "https://finance.yahoo.com/news/asia-shares-mixed-wall-street-040948016.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "4043cad5-ab05-3cad-b585-6048f9af8a8d",
      "content": {
        "id": "4043cad5-ab05-3cad-b585-6048f9af8a8d",
        "contentType": "STORY",
        "title": "Asian shares gained and gold and silver climb higher after a retreat on Wall St",
        "description": "",
        "summary": "Asia shares traded mostly higher on Wednesday despite a retreat on Wall Street on selling of technology stocks, while gold and silver continued to regain ground after a recent sell-off. U.S. futures edged higher and oil prices advanced. The future for the S&P 500 edged up 0.2%, while that for the Dow Jones Industrial Average rose 0.3%.",
        "pubDate": "2026-02-04T04:09:48Z",
        "displayTime": "2026-02-04T04:09:48Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ap_finance_articles_694/abef10a7a0d2b376230e6c832f9632e9",
          "originalWidth": 5258,
          "originalHeight": 3505,
          "caption": "Specialist Anthony Matesic works at his post on the floor of the New York Stock Exchange, Monday, Feb. 2, 2026. (AP Photo/Richard Drew)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/39HZ9JJXKwbFiiUJWDJsXg--~B/aD0zNTA1O3c9NTI1ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/ap_finance_articles_694/abef10a7a0d2b376230e6c832f9632e9.cf.webp",
              "width": 5258,
              "height": 3505,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dmRVvUcSg0IhXfwyFtGEaQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ap_finance_articles_694/abef10a7a0d2b376230e6c832f9632e9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/asia-shares-mixed-wall-street-040948016.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/asia-shares-mixed-wall-street-040948016.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "GC=F"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "SI=F"
            },
            {
              "symbol": "DX-Y.NYB"
            },
            {
              "symbol": "SFTBF"
            },
            {
              "symbol": "EUR=X"
            },
            {
              "symbol": "ADTTF"
            },
            {
              "symbol": "SSNLF"
            },
            {
              "symbol": "000660.KS"
            },
            {
              "symbol": "^AXJO"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "TOELF"
            },
            {
              "symbol": "NTDOF"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "PYPL"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MSFT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T09:00:00+00:00",
    "headline": "Levicept Announces the Appointment of James Sandy as Chief Development Officer",
    "summary": "Leadership Team Strengthened to Support Clinical Development of LEVI-04 for OsteoarthritisSANDWICH, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the appointment of James Sandy as Chief Development Officer (CDO). James brings over 30 years’ experience in the pharmaceutical and biotechnology industries covering a wide range of therapeutic areas and d",
    "url": "https://finance.yahoo.com/news/levicept-announces-appointment-james-sandy-090000714.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "b08b841e-1968-3400-8850-8deaf2085284",
      "content": {
        "id": "b08b841e-1968-3400-8850-8deaf2085284",
        "contentType": "STORY",
        "title": "Levicept Announces the Appointment of James Sandy as Chief Development Officer",
        "description": "",
        "summary": "Leadership Team Strengthened to Support Clinical Development of LEVI-04 for OsteoarthritisSANDWICH, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the appointment of James Sandy as Chief Development Officer (CDO). James brings over 30 years’ experience in the pharmaceutical and biotechnology industries covering a wide range of therapeutic areas and d",
        "pubDate": "2026-02-04T09:00:00Z",
        "displayTime": "2026-02-04T09:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2873fb7be738612944bae7961e6edbce",
          "originalWidth": 188,
          "originalHeight": 57,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6mYeXoicbodWtShtPrg.ww--~B/aD01Nzt3PTE4ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/2873fb7be738612944bae7961e6edbce.cf.webp",
              "width": 188,
              "height": 57,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MNF0Te8tICDYen70USuKPw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2873fb7be738612944bae7961e6edbce.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/levicept-announces-appointment-james-sandy-090000714.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/levicept-announces-appointment-james-sandy-090000714.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]